Biodexa Pharmaceuticals Plc PEG Ratio

The latest PEG ratio for BDRX is 91.69. That is above the Healthcare sector average of 12.15. Investors often review this figure alongside Biodexa Pharmaceuticals Plc's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, BDRX currently prints 91.69 for PEG ratio, while the sector average sits near 12.15. That is roughly 654.4% above the sector mean. Large gaps often invite a closer look at Biodexa Pharmaceuticals Plc's growth, margins, and balance sheet.

A PEG ratio of 91.69 for Biodexa Pharmaceuticals Plc is not 'good' or 'bad' on its own. Compare it with the peer average (12.15) and with BDRX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting BDRX's PEG ratio (91.69), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Biodexa Pharmaceuticals Plc's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.